Implementierungsleitfaden Therapieziele Onkologie - Local Development build (v1.0.0-ballot) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON

: EnLiST-Änderungstypen

Draft as of 2026-08-03

Raw json | Download

{
  "resourceType" : "CodeSystem",
  "id" : "enlist-change-type",
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem enlist-change-type</b></p><a name=\"en-enlist-change-type\"> </a><a name=\"en-hcenlist-change-type\"> </a><p>This case-sensitive code system <code>https://bih-cei.de/fhir/therapieziele-onkologie/CodeSystem/enlist-change-type</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">new<a name=\"en-enlist-change-type-new\"> </a></td><td>New LoT</td><td>Neue Linie (X+1): klinische Progression (cPD) oder fehlendes adäquates Ansprechen.</td></tr><tr><td style=\"white-space:nowrap\">modified<a name=\"en-enlist-change-type-modified\"> </a></td><td>Modified LoT</td><td>Modifizierte Linie (Y+1): nicht-progressionsbedingte Änderung — Intoleranz, Hinzunahme/Wechsel eines Wirkstoffs, finanzielle oder logistische Gründe.</td></tr><tr><td style=\"white-space:nowrap\">same<a name=\"en-enlist-change-type-same\"> </a></td><td>Same LoT</td><td>Unveränderte Designation: prospektiv geplante Änderungen — Dosis, Zeitplan, Applikationsweg, Erhaltungstherapie, Therapiepause mit unveränderter Reintroduktion.</td></tr></table></div>"
  },
  "url" : "https://bih-cei.de/fhir/therapieziele-onkologie/CodeSystem/enlist-change-type",
  "version" : "1.0.0-ballot",
  "name" : "EnlistChangeType",
  "title" : "EnLiST change types",
  "status" : "draft",
  "date" : "2026-08-03T05:20:25+00:00",
  "publisher" : "Berlin Institute of Health at Charité (BIH)",
  "contact" : [
    {
      "name" : "Berlin Institute of Health at Charité (BIH)",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://www.bihealth.org"
        }
      ]
    }
  ],
  "description" : "The three change types of the EnLiST counting logic: new LoT — X plus one, only on progression or lack of adequate response; modified LoT — Y plus one, non-progression-related change; same LoT — prospectively planned change, designation unchanged. Intended for flagging treatment changes at request level.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "DE",
          "display" : "Germany"
        }
      ]
    }
  ],
  "caseSensitive" : true,
  "content" : "complete",
  "count" : 3,
  "concept" : [
    {
      "code" : "new",
      "display" : "New LoT",
      "definition" : "Neue Linie (X+1): klinische Progression (cPD) oder fehlendes adäquates Ansprechen."
    },
    {
      "code" : "modified",
      "display" : "Modified LoT",
      "definition" : "Modifizierte Linie (Y+1): nicht-progressionsbedingte Änderung — Intoleranz, Hinzunahme/Wechsel eines Wirkstoffs, finanzielle oder logistische Gründe."
    },
    {
      "code" : "same",
      "display" : "Same LoT",
      "definition" : "Unveränderte Designation: prospektiv geplante Änderungen — Dosis, Zeitplan, Applikationsweg, Erhaltungstherapie, Therapiepause mit unveränderter Reintroduktion."
    }
  ]
}